Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial

Type 2 diabetes mellitus (T2DM) is characterized by systemic metabolic abnormalities and the development of micro- and macrovascular complications, resulting in a shortened life expectancy. A recent cardiovasc...
Source: Cardiovascular Diabetology - Category: Cardiology Authors: Source Type: research

Related Links:

Resumo Investigar os fatores associados ao controle glic êmico de pessoas com diabetes mellitus (DM). Estudo transversal realizado com 746 pessoas com DM tipo 2 e 40 anos ou mais de idade. Elegeu-se as seguintes variáveis: socioeconômicas, dados clínicos, estilo de vida e o risco para o desenvolvimento de úlceras nos pés. A coleta dos dados ocorreu por meio de entrevista, análise do prontuário e exame clínico dos membros inferiores. Utilizou-se o modelo de regressão múltipla de Poisson para determinação das razões de preval&ecir...
Source: Ciencia e Saude Coletiva - Category: Occupational Health Source Type: research
SUMMARY Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are drugs that act by maintaining glycosuria. Recent studies have shown promising effects of these in the treatment of type 2 diabetes mellitus (DM2). However, there may be an increased risk of developing urinary tract infections (UTIs) in patients treated with these. Our study aims to analyze the association between the risk of UTI in patients treated with SGLT2i. A systematic review of the literature was carried out by randomized clinical trials, totalizing at the end of the selection 23 articles that were statistically evaluated. The incidence of UTI was general...
Source: Revista da Associacao Medica Brasileira - Category: General Medicine Source Type: research
Publication date: Available online 18 March 2019Source: Meta GeneAuthor(s): Shania Abidi Nee Abbas, Syed Tasleem Raza, Snober S. Mir, Zeba Siddiqi, Alina Zaidi, ZeashanHaider Zaidi, Farzana MahdiAbstractBackgroundDiabetes mellitus is a metabolic disorder which can affects the body's ability to produce or use of the hormone insulin leads to high blood sugar levels and it may serves as a host of complications. Emerging evidence suggests that common and rare genetic polymorphisms can influence the risk of developing diabetic complications. We attempt to evaluate the association of (rs7903146 and rs290487) variants of TCF7L2 g...
Source: Meta Gene - Category: Genetics & Stem Cells Source Type: research
This study is a randomized clinical trial that was conducted on 100 married women aged 35-55  year old with type 2 diabetes referred to endocrinology clinic. The subjects were randomly assigned to the intervention and control groups. In the intervention group, individual counseling was designed based on PLISSIT model, in at least three sessions. The control group received a general health training pamphlet at the end of the study. Before the first session and then 4 and 8 weeks after the intervention, questionnaires of demographic information, Brief Sexual symptom checklist for women (BSSC-W), and Female sexual F...
Source: International Journal of Diabetes in Developing Countries - Category: Endocrinology Source Type: research
ConclusionSeveral clinical trials have confirmed the relationship between the consumption of coffee and the development of T2DM. Moderate consumption of coffee has been suggested for its long-term benefits and positive health effects.
Source: Journal of Public Health - Category: Health Management Source Type: research
Leonard Gray Conventional outpatient services are unlikely to meet burgeoning demand for diabetes services given increasing prevalence of diabetes, and resultant impact on the healthcare workforce and healthcare costs. Disruptive technologies (such as smartphone and wireless sensors) create an opportunity to redesign outpatient services. In collaboration, the Department of Diabetes and Endocrinology at Brisbane Princess Alexandra Hospital, the University of Queensland Centre for Health Services Research and the Australian e-Health Research Centre developed a mobile diabetes management system (MDMS) to support the mana...
Source: International Journal of Environmental Research and Public Health - Category: Environmental Health Authors: Tags: Protocol Source Type: research
ConclusionsThrough the evaluation up to 672  days, semaglutide, liraglutide, and empagliflozin decreased the risk of MACE. Concerning the risk of each cardiovascular event, risk reduction was seen with empagliflozin and canagliflozin.
Source: Clinical Drug Investigation - Category: Drugs & Pharmacology Source Type: research
Authors: Seo DH, Kim SH, Song JH, Hong S, Suh YJ, Ahn SH, Woo JT, Baik SH, Park Y, Lee KW, Kim YS, Nam M, KNDP Study Group Abstract BACKGROUND: Recent evidences indicate that early rapid renal function decline is closely associated with the development and progression of diabetic kidney disease. We have investigated the association between carotid atherosclerosis and rapid renal function decline in patients with type 2 diabetes mellitus and preserved renal function. METHODS: In a prospective, multicenter cohort, a total of 967 patients with type 2 diabetes mellitus and preserved renal function were followed for...
Source: Diabetes and Metabolism Journal - Category: Endocrinology Tags: Diabetes Metab J Source Type: research
CONCLUSION: Higher VVV of SBP was associated with an increased risk of CVD, irrespective of the mean SBP level. Future studies are needed to confirm these findings. PMID: 30877712 [PubMed - as supplied by publisher]
Source: Diabetes and Metabolism Journal - Category: Endocrinology Tags: Diabetes Metab J Source Type: research
This study aimed to evaluate the efficacy and safety of sodium-glucose cotransporter-2 (SGLT2) inhibitors in Korean patients who had inadequately controlled type 2 diabetes mellitus (T2DM) in real-world clinical practice. METHODS: We included 410 patients who started SGLT2 inhibitors (empagliflozin or dapagliflozin) as add-on therapy or switch therapy between February 2015 and June 2017. The primary efficacy endpoint was a change in glycosylated hemoglobin (HbA1c) from baseline to week 12. The secondary endpoints were patients achieving HbA1c
Source: Diabetes and Metabolism Journal - Category: Endocrinology Tags: Diabetes Metab J Source Type: research
More News: Cardiology | Cardiovascular | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Empagliflozin | Endocrinology | Heart | Jardiance